Prostate Cancer Metastatic to Bone Clinical Trial
Official title:
A Prospective Study Comparing the Diagnostic Accuracy of Bone SPECT-CT, Choline-PET-CT, PSMA-PET-CT, NaF-PET-CT and WB-MRI in the Detection of Prostate Cancer Bone Metastases
An improved diagnosis of bone metastases in prostate cancer patients can have a significant
impact on treatment strategy and probably survival as well.
The primary purpose of the project is to determine the diagnostic accuracy of bone SPECT-CT,
choline-PET-CT, PSMA-PET-CT, NaF-PET-CT and Whole-body MRI in the diagnosis of bone
metastases in prostate cancer patients.
The project is a prospective diagnostic test accuracy study. The project takes place at
Herlev Hospital and is a collaboration between the Department of Radiology and the
Department of Clinical Physiology and Nuclear Medicine.
The investigators want to include 300 prostate cancer patients referred to our standard
diagnostic imaging (NaF-PET-CT scan) by the clinicians.
In addition to the standard diagnostic imaging (NaF-PET-CT-scan), two project will be
performed on all participants. The project has three arms with the following scanning
combinations:
A) Whole-body MRI + SPECT-CT B) Whole-body MRI + Cholin-PET-CT C) Whole-body MRI +
PSMA-PET-CT The recruitment of project participants takes place on the day when the patients
are undergoing a NaF-PET-CT scan in the course of regular clinical practice at our
institution.
All readers are experienced radiologists or specialists in nuclear medicine. Patient
identification on each scan will be anonymized and the reader will not have access to
clinical and biochemical information or previous imaging studies.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06430411 -
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
|
||
| Active, not recruiting |
NCT03458559 -
Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy
|
Phase 3 | |
| Withdrawn |
NCT04483414 -
68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer
|
Phase 2 | |
| Completed |
NCT03304418 -
Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone
|
Phase 2 |